Skip to main content
About
Company Profile
Management Team
Board of Directors
Scientific Advisory Board
Science
Overview
CD47
Pipeline
Overview
TTI-621
TTI-622
For Patients
Overview
TTI-621-01
TTI-622-01
Investors
Contact
Contact Information
Careers
Menu
Investors
Stock Information
Stock Quote & Chart
Historical Price Lookup
Analyst Coverage
Financial Information
SEC Filings
Financial Reports
Corporate Governance
Management Team
Board of Directors
Governance Documents
2021 Annual and Special Meeting
Press Releases
Events & Presentations
Trillium R&D Day
Investor Resources
Contact Investor Relations
FAQs
Email Alerts
RSS
Normal
Press Release RSS Feed (opens in new window)
Press Releases
Press release year list
2021
2020
2019
2018
2017
2016
2015
2014
2013
Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders
June 9, 2021
Download
PDF format download (opens in new window)
Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results
May 7, 2021
Download
PDF format download (opens in new window)
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
April 28, 2021
Download
PDF format download (opens in new window)
Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes
April 28, 2021
Download
PDF format download (opens in new window)
Trillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021
April 22, 2021
Download
PDF format download (opens in new window)
Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day
March 18, 2021
Download
PDF format download (opens in new window)